

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/923,270	08/03/2001	Jurgen Kleinschmidt	31304-704.831	3472
21971	7590 11/15/2005		EXAMINER	
WILSON SONSINI GOODRICH & ROSATI 650 PAGE MILL ROAD			· WINKLER	, ULRIKE
), CA 94304-1050		ART UNIT	PAPER NUMBER
	.,		1648	

DATE MAILED: 11/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	-
	09/923,270	KLEINSCHMIDT ET AL.	
Office Action Summary	Examiner	Art Unit	
·	Ulrike Winkler	1648	
The MAILING DATE of this commun	ication appears on the cover sheet v	vith the correspondence address	
A SHORTENED STATUTORY PERIOD F WHICHEVER IS LONGER, FROM THE M - Extensions of time may be available under the provisions after SIX (6) MONTHS from the mailing date of this comn - If NO period for reply is specified above, the maximum st - Failure to reply within the set or extended period for reply Any reply received by the Office later than three months a earned patent term adjustment. See 37 CFR 1.704(b).	IAILING DATE OF THIS COMMUN of 37 CFR 1.136(a). In no event, however, may a nunication. atutory period will apply and will expire SIX (6) MO will, by statute, cause the application to become A	ICATION. I reply be timely filed INTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).	
Status			
Responsive to communication(s) file This action is FINAL Since this application is in condition closed in accordance with the practi	2b) This action is non-final. for allowance except for formal ma		,
Disposition of Claims			
4) Claim(s) 13-27 is/are pending in the 4a) Of the above claim(s) is/a 5) Claim(s) 13-19 is/are allowed. △ 1 l 6) Claim(s) 20-27 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restrict	re withdrawn from consideration.		
Application Papers			
11)☐ The oath or declaration is objected to	a) accepted or b) objected to ction to the drawing(s) be held in abeyong the correction is required if the drawing	ance. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
2. Certified copies of the priority3. Copies of the certified copies	documents have been received. documents have been received in of the priority documents have bee onal Bureau (PCT Rule 17.2(a)).	Application No n received in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (F	PTO-948) Paper No	Summary (PTO-413) b(s)/Mail Date	
Information Disclosure Statement(s) (PTO-1449 or Paper No(s)/Mail Date	PTO/SB/08) 5) Notice of 6) Other: _	Informal Patent Application (PTO-152)	

DETAILED ACTION

The Amendment filed August 29, 2005 in response to the Office Action of May 3, 2005 is acknowledged and has been entered. Claims 13-27 are pending and are currently being examined.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.

The rejection of claims 13, 15, 17, 20-27 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention **is withdrawn** in view of Applicants amendment to the claims.

The rejection of claims 17 are 20-27 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement is withdrawn in view of Applicants arguments.

The rejection of claims 20-27 under 35 U.S.C. 112, second paragraph, as being incomplete for omitting essential steps, such omission amounting to a gap between the steps is maintained. Applicants' amendments to the claims have not clarified at what point during the method the nucleic acid comprising the rAAV is introduced into the cells.

The omitted steps are: inserting the rAAV nucleic acid construct into the cell. It is not clear from the specification where the rAAV structures come from, they could either be already

Art Unit: 1648

part of the cell and integrated into the genome of the cell or they could be transfected into the cell at the same time the AAV/AD5 nucleic acid construct is inserted into the cell.

The instant claims are drawn to a method of producing the rAAV particles yet in the method steps it is not clear where the nucleic acids necessary for developing the rAAV comes from and at what point the rAAV genes are inserted into the cells. The Office understands the role of the AAV/AD5 nucleic acid construct is to help the rAAV construct to be packed into a particle. In the instant method steps it is not clear at what point the nucleic acid construct for the rAAV is inserted into the cell.

The objection of claims 17 are 20-27 is withdrawn in view of Applicants amendment to the claims spelling out recombinant adeno-virus (rAAV) the first time it is used in a claim.

Conclusion

Claims 20-27 are rejected.

Claims 14-19 are allowable.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period

Art Unit: 1648

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG (November 15, 1989). The Group 1600 Official Fax number is: (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Tech Center representative whose telephone number is (571)-272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ulrike Winkler, Ph.D. whose telephone number is 571-272-0912. The examiner can normally be reached M-F, 8:30 am - 5 pm. The examiner can also be reached via email [ulrike.winkler@uspto.gov].

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached at 571-272-0902.

ULRIKE WINKLER, PH.D.
PRIMARY EXAMINER 11/14/05